| First Author | Lee JO | Year | 2020 |
| Journal | FEBS J | Volume | 287 |
| Issue | 10 | Pages | 2087-2104 |
| PubMed ID | 32196931 | Mgi Jnum | J:305700 |
| Mgi Id | MGI:6705282 | Doi | 10.1111/febs.15301 |
| Citation | Lee JO, et al. (2020) The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKalpha2. FEBS J 287(10):2087-2104 |
| abstractText | Meteorin-like (metrnl) is a recently identified adipomyokine that beneficially affects glucose metabolism; however, its underlying mechanism of action is not completely understood. We here show that the level of metrnl increases in vitro under electrical pulse stimulation and in vivo in exercised mice, suggesting that metrnl is secreted during muscle contractions. In addition, metrnl increases glucose uptake via the calcium-dependent AMPKalpha2 pathway in skeletal muscle cells and increases the phosphorylation of HDAC5, a transcriptional repressor of GLUT4, in an AMPKalpha2-dependent manner. Phosphorylated HDAC5 interacts with 14-3-3 proteins and sequesters them in the cytoplasm, resulting in the activation of GLUT4 transcription. An intraperitoneal injection of recombinant metrnl improved glucose tolerance in mice with high-fat-diet-induced obesity or type 2 diabetes, but not in AMPK beta1beta2 muscle-specific null mice. Metrnl improves glucose metabolism via AMPKalpha2 and is a promising therapeutic candidate for glucose-related diseases such as type 2 diabetes. |
